sales@ambeed.com

Structure Search

List Search MOL Search Structure Search

Hello, Sign in

Home Cart 0 Sign in

X

[ CAS No. 142685-25-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

DV 2D 3D

3d Animation Molecule Structure of 142685-25-4

Chemical Structure| 142685-25-4

Chemical Structure| 142685-25-4

Structure of 142685-25-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 142685-25-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 142685-25-4 ]

SDS Specification

Alternatived Products of [ 142685-25-4 ]

Product Details of [ 142685-25-4 ]

CAS No. :	142685-25-4	MDL No. :	MFCD07784266
Formula :	C₈HF₇O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	OJLSSULCTKBVOB-UHFFFAOYSA-N
M.W :	262.08	Pubchem ID :	15334258
Synonyms :

Safety of [ 142685-25-4 ]

Signal Word:	Danger	Class:	3
Precautionary Statements:	P210-P233-P240-P241-P242-P243-P261-P264-P271-P280-P303+P361+P353-P304+P340+P312-P305+P351+P338-P337+P313-P362-P370+P378-P403+P233+P235-P405-P501	UN#:	3272
Hazard Statements:	H225-H315-H319-H335	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 142685-25-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 142685-25-4 ]

[ 142685-25-4 ] Synthesis Path-Downstream 1~52

1
[ 142685-25-4 ]
[ 78072-68-1 ]
[ 170962-90-0 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

2
[ 142685-25-4 ]
Succinic acid mono-((3R,5R,8R,9S,10S,13R,14S,17R)-17-{(R)-4-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-1-methyl-butyl}-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-yl) ester [ No CAS ]
Succinic acid (3R,5R,8R,9S,10S,13R,14S,17R)-17-{(R)-4-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-1-methyl-butyl}-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-yl ester 2,3,5,6-tetrafluoro-phenyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

3
[ 142685-25-4 ]
Succinic acid mono-[(3R,5S)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-((8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxycarbonyl)-pyrrolidin-3-yl] ester [ No CAS ]
Succinic acid (3R,5S)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-((8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yloxycarbonyl)-pyrrolidin-3-yl ester 2,3,5,6-tetrafluoro-phenyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

4
[ 142685-25-4 ]
C₅₆H₇₅NO₉ [ No CAS ]
C₆₂H₇₅F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

5
[ 142685-25-4 ]
Succinic acid mono-{(3R,5S)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-methoxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoyl]-pyrrolidin-3-yl} ester [ No CAS ]
Succinic acid (3R,5S)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-[(R)-4-((3R,5R,8R,9S,10S,13R,14S,17R)-3-methoxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoyl]-pyrrolidin-3-yl ester 2,3,5,6-tetrafluoro-phenyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

6
[ 142685-25-4 ]
[ 142685-24-3 ]
C₆₃H₇₇F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

7
[ 142685-25-4 ]
[ 141287-80-1 ]
C₆₃H₇₇F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

8
[ 142685-25-4 ]
[ 133966-32-2 ]
C₆₄H₇₇F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

9
[ 142685-25-4 ]
Succinic acid mono-{(3R,5S)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-1-[(3S,5S,8R,9S,10S,13R,14S,17R)-17-((1R,4R)-4-ethyl-1,5-dimethyl-hexyl)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-yloxycarbonyl]-pyrrolidin-3-yl} ester [ No CAS ]
C₆₆H₈₃F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

10
[ 142685-25-4 ]
C₆₀H₇₉NO₉ [ No CAS ]
C₆₆H₇₉F₄NO₉ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

11
[ 142685-25-4 ]
Succinic acid mono-{(3R,5S)-1-(2,3-bis-hexadecyloxy-propoxycarbonyl)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-pyrrolidin-3-yl} ester [ No CAS ]
Succinic acid (3R,5S)-1-(2,3-bis-hexadecyloxy-propoxycarbonyl)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-pyrrolidin-3-yl ester 2,3,5,6-tetrafluoro-phenyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4587 - 4596

12
[ 142685-25-4 ]
[ 22813-32-7 ]
[ 199734-70-8 ]

Reference： [1]Bioorganic and Medicinal Chemistry,2001,vol. 9,p. 665 - 675
[2]Journal of labelled compounds and radiopharmaceuticals,1997,vol. 40,p. 56 - 57

13
[ 142685-25-4 ]
C₁₆H₁₆N₂O₄*C₆H₁₅N [ No CAS ]
C₂₂H₁₆F₄N₂O₄ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

14
[ 142685-25-4 ]
C₁₆H₁₆N₂O₄*C₆H₁₅N [ No CAS ]
(8aS)-2,3,5,6-tetrafluorophenyl 1,2,8,8a-tetrahydro-7-methyl-4-oxo-cyclopropa[c]pyrrolo[3,2-e]indole-2-succinate [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

15
[ 142685-25-4 ]
C₁₇H₁₈N₂O₄*C₆H₁₅N [ No CAS ]
C₂₃H₁₈F₄N₂O₄ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

16
[ 142685-25-4 ]
C₁₇H₁₈N₂O₄*C₆H₁₅N [ No CAS ]
(8aS)-2,3,5,6-tetrafluorophenyl 1,2,8,8a-tetrahydro-5,7-dimethyl-4-oxo-cyclopropa[c]pyrrolo[3,2-e]indole-2-succinate [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

17
[ 142685-25-4 ]
C₂₇H₂₄N₄O₅*C₆H₁₅N [ No CAS ]
C₃₃H₂₄F₄N₄O₅ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

18
[ 142685-25-4 ]
C₂₇H₂₄N₄O₅*C₆H₁₅N [ No CAS ]
C₃₃H₂₄F₄N₄O₅ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

19
[ 142685-25-4 ]
C₂₈H₂₆N₄O₅*C₆H₁₅N [ No CAS ]
C₃₄H₂₆F₄N₄O₅ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

20
[ 142685-25-4 ]
C₂₈H₂₆N₄O₅*C₆H₁₅N [ No CAS ]
[ 192657-33-3 ]

Reference： [1]Journal of the American Chemical Society,1997,vol. 119,p. 6214 - 6225

21
[ 142685-25-4 ]
N-methyl-N-biotinylglycine [ No CAS ]
biotin-N-methylglycine 2,3,5,6-tetrafluorophenyl ester [ No CAS ]

Reference： [1]Journal of labelled compounds and radiopharmaceuticals,1998,vol. 41,p. 595 - 603

22
[ 142685-25-4 ]
[ 178446-63-4 ]
[ 380607-61-4 ]

Reference： [1]Journal of labelled compounds and radiopharmaceuticals,2001,vol. 44,p. S741 - S743

23
[ 769-39-1 ]
[ 407-25-0 ]
[ 142685-25-4 ]

Yield	Reaction Conditions	Operation in experiment
93%	boron trifluoride diethyl etherate;Heating / reflux;	Using a known procedure [Nucleic Acids Res 1993, 21, 145], a mixture of 2,3, 5,6- TETRAFLUOROPHENOL (55.2 g, 0.33 MOL), trifluoroacetic anhydride (60 ML, 0.42 mol) and boron TRIFLUORIDE etherate (0.5 ML) was REFLUXED for 16 hr. TRIILUOROACETIC anhydride and trifluoroacetic acid were removed by distillation at atmospheric pressure. The trifluoroacetic anhydride fiaction (bp 40C) was returned to the reaction mixture along with 0. 5 ML of boron trifluoride etherate, and the MIXTURE WAS REFLUXED for 24 hr. This process was repeated two times to ensure complete reaction. After distillation at atmospheric pressure, the desired product was collected at 62C/45 mm (45C/18 mm) as a colorless liquid : yield: 81.3 (93%); d = 1.52 g/mL; IR (CHCI3) 3010,1815, 1525,1485, 1235, TL80, and 955 cm-1.

Reference： [1]Patent: WO2005/32598,2005,A1 .Location in patent: Page/Page column 71; 72
[2]Bioorganic and Medicinal Chemistry,2001,vol. 9,p. 665 - 675
[3]Journal of the American Chemical Society,2008,vol. 130,p. 16466 - 16467

24
[ 259674-48-1 ]
[ 142685-25-4 ]
1,4-cyclohexadiene-1-pentanoic acid 2,5-bis(1-aziridinyl)-4-methyl-3,6-dioxo 2,3,5,6-tetrafluorophenyl ester [ No CAS ]

Reference： [1]Journal of the American Chemical Society,1998,vol. 120,p. 9729 - 9734

25
[ 142685-25-4 ]
[ 58-85-5 ]
[ 173341-32-7 ]

Yield	Reaction Conditions	Operation in experiment
83%	With triethylamine; In N,N-dimethyl-formamide; at 20℃; for 0.5h;Product distribution / selectivity;	EXAMPLE 1; Method for Synthesizing an Activated Ester of a Biotin Moiety The following Example sets forth a methodology for preparing a tetrafluorophenyl (TFP) ester of a biotin moiety that is subsequently reacted with a water-soluble linker moiety and then a cross-linker of at least tri-functionality to produce a biotin-containing compound according to the invention. Other methods for preparing activated esters generally known in the field can be used to prepare biotin activated esters containing any number of phenolic and other hydroxyl (e.g., N-hydroxylsuccinimide) groups. Preparation of Biotin Tetrafluorophenyl Ester Biotin (10 g, 40.9 mmol) was dissolved in 200 mL warm (70 C.) DMF under an argon atmosphere. The solution was allowed to cool to ambient temperature and 10 mL (82 mmol) triethylamine was added, followed by the addition of 16 g (61 mmol) of <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>. The reaction was stirred at room temperature for 30 min and solvent was removed under vacuum. The product was triturated in 100 mL ether and then filtered. The reaction scheme is shown below. The isolated product was dried under vacuum to yield 14 g (83%) of biotin TFP ester as a colorless solid, mp=185-187 C. 1H NMR (DMSOd6, δ): 1.4-1.8 (m, 6H), 2.5 (m, 1H), 2.6-2.9 (m, 3H), 3.1 (m, 1H), 4.2 (m, 1H), 6.4 (d, 2H), 7.9 (m, 1H); 1R (KBr, cm-1) 3250, 2915, 1790, 1710, 1520, 1520, 1480, 1090; Reaction Step 3: Biotin Tetrafluorophenyl Ester This compound was prepared by reaction of biotin with <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong> as described in Example 1.
63 - 80%	With triethylamine; In DMF (N,N-dimethyl-formamide); at 20 - 25℃; for 0.5h;Product distribution / selectivity;	Biotin (1.0 g, 4.1 mmol) was dissolved in 20 mL of DMF (70C) under argon atmosphere. To the solution at 25C, 1 mL (8 mmol) of triethylamine was added followed by the addition of 1.7 (6, 1 mmol) of 2, 3, 5, 6-TETRAFHTOROROPHENYL TRIFLUOROACETATE. The reaction was stirred at room temperature for 30 min and solvent was removed under vacuum. The product was triturated in 10 mL of ether and filtered. The isolated product was dried under vacuum to yield 1.3 (80%) of biotin TFP ester as a colorless solid: mp: 185-187 C ; IH NMR (DMSO-d6, 0) 1.4-1. 8 (M, 6H), 2.5 (M, IH), 2. 6-2. 9 (m, 3H), 3.1 (M, IH), 4.2 (M, IH), 6.4 (d, 2H), 7.9 (M, 1 H) ; IR (KBr, cm-1) 3250, 2915, 1790, 1710,1520, 1480, 1090.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 22-23; 26
[2]Patent: WO2005/32598,2005,A1 .Location in patent: Page/Page column 72; 76
[3]Bioconjugate Chemistry,2010,vol. 21,p. 1225 - 1238

26
[ 295322-40-6 ]
[ 142685-25-4 ]
[ 195152-91-1 ]

Yield	Reaction Conditions	Operation in experiment
80%	With triethylamine; In DMF (N,N-dimethyl-formamide); at 25℃; for 1.0h;	3-(BIOTINAMIDO) butyric acid (1.0 3.1 mmol) dissolved in 10 mL of DMF under argon atmosphere was added 1. 0 (3.65 mmol) of TFP-OTFA, followed by 0.1 mL of triethylamine. The reaction mixture was stirred at 25C for 1 h and the solvent was removed under vacuum. The residue was extracted into CH3Cl (4 x 20 mL). The combined CHSCI extracts were washed with saturated aqueous NAHC03 (2 x 10 mL) and water (2 x 10 mL). The CH3Cl solution was dried over anhydrous Na2SO4, and the solvent was removed by vacuum. The product was dried to yield 1.1 g (80%) of as a colorless SOILD, mp 137-139C. 1H NMR (DMSO-d6): d 7.7 (M, 2H), 6.2 (d, J= 13.2 IIZ, 2EI), 3.9-4. 2 (m, 3H), 2.5-2. 7 (M, 4H), 2.35 (D, J= 12.6 Hz, 1H), 1.85 (t, J= 7.0 Hz, 2H), 0. 7-1. 5 (m, 10H).

Reference： [1]Patent: WO2005/32598,2005,A1 .Location in patent: Page/Page column 73

27
[ 89619-93-2 ]
[ 7087-68-5 ]
[ 142685-25-4 ]
[ 852178-14-4 ]

Yield	Reaction Conditions	Operation in experiment
	In DMF (N,N-dimethyl-formamide); at 20℃; for 3.0h;	Preparation of a tetrafluorophenyl thiosulfate compound [0178] To a solution of bromoacetic acid (20 g, 0.144 mol) in 100 mL of methanol was added a solution of sodium thiosulfate pentahydrate (40 g, 0.161 mol) in 150 mL of water and the mixture was stirred at room temperature for 2 hours. It was then concentrated in vacuo and the resulting residue was suspended in 50 mL of methanol. It was filtered to remove NaBr and the filtrate was concentrated in vacuo. The resulting residue was suspended with acetone (150 mL) and heated under reflux for 15 minutes. It was filtered while warm and the filter cake was heated under reflux with fresh acetone for 15 minutes. This extraction with acetone was done two more times. The combined acetone solution was concentrated to a volume of about 30 mL. The resulting colorless solid was collected by filtration to give 10 g of carboxymethyl thiosulfate, sodium salt. To a solution of this carboxymethyl thiosulfate, sodium salt (1.95 g, 0.010 mol) in 15 mL of DMF was added N, N-diisopropylethylamine (2.2 mL, 0.013 mol), followed by addition of 2,3, 5,6-tetrafluorophenyl trifluoroacetate (3.4 g, 0.013 mol). After the reaction mixture was stirred at room temperature for 3 hours, it was added dropwise into about 250 mL of ether and stirred for 1 hour. The ether solution was carefully decanted and a second volume (250 mL) of ether was added to the residue. After being stirred for 1 hour, the resulting solid was collected by filtration and washed with ether (3x15 mL) to give 2.35 g of a colorless powdery solid. TLC: Rf= 0.28 (silica gel, 30% methanol in chloroform 1HNMR (D20), 8 7.28-7. 15 (m, 1H, ArH), 4.19 (s, 2H, CH2), 3.66- 3.50 (m, 2H, 2x CH), 1.23 (t, 3H, CH3), 1.20 (t, 6H, 2x CH3). The structure of the resulting tetrafluorophenyl thiosulfate compound is provided below in Formula (EI).

Reference： [1]Patent: WO2005/47242,2005,A2 .Location in patent: Page/Page column 45

28
C₈H₁₄NO₆S₂^(1-)*Na⁽¹⁺⁾ [ No CAS ]
[ 142685-25-4 ]
[ 852178-15-5 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In DMF (N,N-dimethyl-formamide); at 20℃; for 4.0h;	Preparation of a tetrafluorophenyl thiosulfate compound [0180] To a solution of 6-aminohexanoic acid (0. 15 g, 1. 13mmol) in 7 mL of water was added N, N-diisopropylethylamine (320 uL, 1.85 mmol) followed by addition of 2,3, 5,6- tetrafluorophenoxycarbonylmethyl thiosulfate (0.51 g, 1.15 mmol) and the mixture was stirred at room temperature for 1 hour. The whole reaction mixture was poured into ether (100 mL) and the resulting precipitate was collected by filtration. After being dried in vacuo, it was dissolved in 5 mL of DMF. To this solution was added N, N-diisopropylethylamine (410 pL, 2.35 mmol) followed by addition of 2,3, 5, 6-tetrafluorophenyl trifluoroacetate (0.60 g, 2.35 mmol) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was poured into ether (100 mL) and the resulting precipitate was collected by filtration. This crude product was purified by LH-20 column (Sephadex) eluting with water. It was then converted to sodium form by treating with Dowex 50WX (sodium form) to give 460 mg of a product as a white solid. TLC (silica gel): Rf= 0.45 (30% methanol in chloroform), 1HNMR (D20) : b 1.32-1. 37 (m, 2H, CH2), 1.44-1. 49 (m, 2H, CH2), 1.62-1. 70 (m, 2H, CH2), 2. 68 (t, 2H, CH2), 3.65 (s, 2H, CH2), 7.10-7. 25 (m, 1H, ArH). The structure of the resulting thiosulfate conjugate is provided below in Formula (E2).

Reference： [1]Patent: WO2005/47242,2005,A2 .Location in patent: Page/Page column 45-46

29
[ 142685-25-4 ]
[ 58-85-5 ]
[ 183896-00-6 ]

Yield	Reaction Conditions	Operation in experiment
14 g (83%)	With triethylamine; In N,N-dimethyl-formamide;	Step 3: Preparation of N-(13-amino-4,7,10-trioxatridecanyl)biotinamide. Biotin (10 g, 40.9 mmol) was dissolved in 200 mL warm (70 C.) DMF under argon atmosphere. The solution was allowed to cool to ambient temperature, 10 mL (82 mol) triethylamine was added, followed by the addition of 16 g (61 mmol) <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>. The reaction was stirred at room temperature for 30 min and solvent was removed under vacuum. The product was triturated in 100 mL ether and was filtered. The isolated product was dried under vacuum to yield 14 g (83%) of biotin TFP ester as a colorless solid, mp 185-187 C. 1H NMR (DMSO-d6, (): 1.4-1.8 (m, 6H), 2.5 (m, 1H), 2-6-2.9 (m, 3H), 3.1 (m, 1H), 4.2 (m, 1H), 6.4 (d, 2H), 7.9 (m, 1 A); IR (KBr, cm-1) 3250, 2915, 1790, 1710, 1520, 1480, 1090. Analysis calc. for C16Hl6F4N2O3S: C, 48.98; H, 4.11; N, 7.14. Found: C, 48.90; H, 4.14; N, 6.86.

Reference： [1]Patent: US2002/159994,2002,A1

30
[ 769-39-1 ]
[ 142685-25-4 ]

Yield	Reaction Conditions	Operation in experiment
	With trifluoroborane diethyl ether; trifluoroacetic anhydride;	2,3,5,6-Tetrafluorophenyl trifluoroacetate A mixture of 2,3,5,6-tetrafluorophenol (55.2 g, 0.33 mol), trifluoroacetic anhydride (60 mL, 0.42 mol) and boron trifluoride etherate (0.5 mL) was refluxed for 16 hr. Trifluoroacetic anhydride and trifluoroacetic acid were removed by distillation at atmospheric pressure. The trifluoroacetic anhydride fraction (bp 40 C.) was returned to the reaction mixture along with 0.5 mL of boron trifluoride etherate, and the mixture was refluxed for 24 hr. This process was repeated two times to ensure complete reaction. After distillation at atmospheric pressure, the desired product was collected at 62 C./45 mm (45 C./18 mm) as a colorless liquid: yield=81.3 g (93%); d=1.52 g/mL; nD21=1.3747; IR (CHCl3) 3010, 1815, 1525, 1485, 1235, 1180, 1110, and 955 cm-1. Anal. Calcd for C8HF7O2: C, 36.66; H, 0.38; F, 50.74. Found: C, 36.31; H, 0.43; 30 F, 50.95.
	With trifluoroborane diethyl ether; trifluoroacetic anhydride;	2,3 5,6-Tetrafluorophenyl trifluoroacetate. A mixture of 2,3,5,6-tetrafluorophenol (55.2 g, 0.33 mol), trifluoroacetic anhydride (60 mL, 0.42 mol) and boron trifluoride etherate (0.5 mL) was refluxed for 16 hr. Trifluoroacetic anhydride and trifluoroacetic acid were removed by distillation at atmospheric pressure. The trifluoroacetic anhydride fraction (bp 40 C.) was returned to the reaction mixture along with 0.5 mL of boron trifluoride etherate, and the mixture was refluxed for 24 hr. This process was repeated two times to ensure complete reaction. After distillation at atmospheric pressure, the desired product was collected at 62 C./45 mm (45 C./18 mm) as a colorless liquid: yield=81.3 g (93%); d=1.52 g/mL; nD21 =1.3747; IR (CHCl3) 3010, 1815, 1525, 1485, 1235, 1180, 1110, and 955 cm-1. Anal. Calcd for C8 HF7 O2: C, 36.66; H, 0.38; F, 50.74. Found: C, 36.31; H, 0.43; F, 50.95.

Reference： [1]Patent: US6312953,2001,B1
[2]Patent: US5912340,1999,A

31
hexane-chloroform [ No CAS ]
[ 142685-25-4 ]
[ 305-03-3 ]
2,3,5,6-Tetrafluorophenyl-4'-[bis(2-chloroethyl)amino] phenylbutyrate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
0.28 g (75%)	With triethylamine; In dichloromethane;	2,3,5,6-Tetrafluorophenyl-4'-[bis(2-chloroethyl)amino] phenylbutyrate (Chlorambucil 2,3,5,6-tetrafluorophenyl ester) To a solution of 0.25 g (0.82 mmol) of chlorambucil (supplied by Fluka A. G.) and 0.3 g (1.1 mmol) of <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong> in 5 ml of dry dichloromethane was added 0.2 Ml of dry triethylamine. The mixture was stirred under argon at room temperature for 0.5 h and evaporated. The residual oil was purified by column chromatography on silica gel with hexane-chloroform (2:1) as the eluding solvent to give the ester as an oil: 0.28 g (75%); TLC on silica gel (CHCl3) Rf 0.6; IR (in CHCl3) 3010, 1780, 1613, 1521, 1485 cm-1.

Reference： [1]Patent: US6143877,2000,A

Yield	Reaction Conditions	Operation in experiment
75%		EXAMPLE XXI 2,3,5,6-Tetrafluorophenyl trifluoroacetate (18) Trifluoroacetic anhydride (28 mL, 0.2 mol) was added dropwise with stirring to 27.1 g (0,163 mol) of 2,3,5,6tetrafluorophenol. Boron trifluoride etherate (0.2 mL) was added and the mixture was refluxed overnight. The residual solution was distilled at atmospheric pressure to remove trifluoroacetic anhydride and trifluoroacetic acid. The desired product 18 (32.2 g; 75% yield) was collected at 45 C. (18mm) as a colorless liquid: d=1.52 g/mL IR (CHCl3) 3010, 1815, 1525, 1485, 1235, 1180, 1110, 955 cm-1. Anal. Calcd for C8HO2 F7: C, 36.66; H, 0.38; F, 50.74. Found: C, 36.31; H, 0.43; F, 50.95.

33
[ 59085-15-3 ]
[ 142685-25-4 ]
[ 915944-73-9 ]

Yield	Reaction Conditions	Operation in experiment
96%	With triethylamine; In N,N-dimethyl-formamide; at 0 - 20℃; for 0.5h;	Synthesis of Compound 65; A 5.0 g (18.1 mmol) quantity of nitromethanetripropionic acid, Compound 64, was dissolved in 10 mL of anhydrous DMF under argon atmosphere. The solution was cooled to 0 C. in an ice bath and Et3N (7.29 g, 10.0 mL, 7.22 mmol) was added, followed by 2,3,5,6-tetrafluorophenol trifluoroacetate (18.9 g, 7.22 mmol). The reaction was allowed to warm to room temperature and the mixture was stirred for an additional 30 min. DMF was removed under vacuum. The pale yellow oily residue was stirred with 200 mL of water in an ice bath for 1 h. Filtration collected Compound 65 as a white solid (12.3 g, 17.3 mmol, 96%), m.p. 133.4-134.4 C. 1HNMR (CDCl3). HRMS calculated for C28H15F12NO8Na (M+Na): 744.0504. Found: 744.0518. HPLC: tR=15.1 min.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 60-61
[2]Bioconjugate Chemistry,2010,vol. 21,p. 1225 - 1238

34
C₁₈H₂₉N₃O₆S [ No CAS ]
[ 142685-25-4 ]
C₂₄H₂₉F₄N₃O₆S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 13 Altering the Charge of Multi-Biotin Containing Compounds From the experiments presented above using the SBDs as the crosslinking agent (C), it was noted that the multi-biotin-containing compounds acquired a net overall charge. The net charge that occurs naturally may be desired in certain applications, but it may also be problematic. Therefore, alteration in the charge of the molecule may be desired. Alteration of the charge is readily achieved by preparing the multibiotin molecules using biotin conjugates, preferentially certain biotin-amino acid conjugates. For example, two biotin-aspartate derivatives (40 and 41) can be formed from the reaction of the appropriately protected aspartic acid as shown below. The aspartate tert-butyl esters 38 and 39 were purchased from a number of commercial sources. Reaction of 38 or 39 with the tetrafluorophenyl (TFP) ester of biotin, provided adducts 40 and 41, respectively, in high yields. The TFP esters of 40 and 41 were readily prepared using tetrafluorophenyl trifluoroacetate to give biotin-aspartate conjugates 42 and 43. Either of these compounds can be reacted with amine (or polyamine) containing compounds (e.g., SBDs) to form multi-biotin-containing compounds. Treatment with trifluoroacetic acid cleaved the t-Bu esters to form free carboxylates. While this reaction yields useful biotin-dendrimer compounds, the preferred biotin-dendrimer compounds contain a water solubilizing linker moiety between the core dendrimer and the biotin derivative. Thus, as a preferred example, the synthesis of a biotin-aspartate derivative, which also contains a trioxtridecane linker and an isothiocyanate moiety for reaction with amines, is depicted below.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 39-40

35
C₁₈H₂₉N₃O₆S [ No CAS ]
[ 142685-25-4 ]
C₂₄H₂₉F₄N₃O₆S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 13 Altering the Charge of Multi-Biotin Containing Compounds From the experiments presented above using the SBDs as the crosslinking agent (C), it was noted that the multi-biotin-containing compounds acquired a net overall charge. The net charge that occurs naturally may be desired in certain applications, but it may also be problematic. Therefore, alteration in the charge of the molecule may be desired. Alteration of the charge is readily achieved by preparing the multibiotin molecules using biotin conjugates, preferentially certain biotin-amino acid conjugates. For example, two biotin-aspartate derivatives (40 and 41) can be formed from the reaction of the appropriately protected aspartic acid as shown below. The aspartate tert-butyl esters 38 and 39 were purchased from a number of commercial sources. Reaction of 38 or 39 with the tetrafluorophenyl (TFP) ester of biotin, provided adducts 40 and 41, respectively, in high yields. The TFP esters of 40 and 41 were readily prepared using tetrafluorophenyl trifluoroacetate to give biotin-aspartate conjugates 42 and 43. Either of these compounds can be reacted with amine (or polyamine) containing compounds (e.g., SBDs) to form multi-biotin-containing compounds. Treatment with trifluoroacetic acid cleaved the t-Bu esters to form free carboxylates. While this reaction yields useful biotin-dendrimer compounds, the preferred biotin-dendrimer compounds contain a water solubilizing linker moiety between the core dendrimer and the biotin derivative. Thus, as a preferred example, the synthesis of a biotin-aspartate derivative, which also contains a trioxtridecane linker and an isothiocyanate moiety for reaction with amines, is depicted below.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 39-40

36
C₂₁H₃₆N₄O₆S [ No CAS ]
[ 142685-25-4 ]
C₂₇H₃₆F₄N₄O₆S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		The foregoing depicts biotin derivatives with added negative charges to multi-biotin-containing compounds. Negatively charged cross-linkers (C) (e.g., polycarboxylates) may require the addition of positively charged biotin derivatives to provide more favorable characteristics to the final biotin-containing compound. In such examples, addition of an appropriately protected lysine to biotin to form an adduct will achieve the desired effect. An example of the synthesis of a biotin-lysine adduct, 48 is provided below.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 43

37
C₁₇H₂₉N₃O₅S [ No CAS ]
[ 142685-25-4 ]
C₂₃H₂₉F₄N₃O₅S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		This compound can be conjugated with chemical entities bearing amines or a linker, such as 4,7,10-trioxa-1,13-tridecanediamine, and added before the reaction with the cross-linker. The t-Boc protecting group can be removed with TFA. The resulting free amine will have a positive charge at physiologic conditions. The net charge of the multibiotin containing compound according to the invention is dependent on the number of biotin-lysine adducts added in addition to the other charged moieties present. The addition of charged species generally improves the water solubility of multi-biotin-containing compounds; however, alteration of charges on the species may not be desired. Therefore, in certain circumstances, it may be desirable to increase the aqueous solubility of biotin multimers by the addition of another, non-charged species. This can be achieved by preparation of a biotin-serine adduct as shown below. Two (2) biotin-serine adducts can be prepared, one with a t-Bu ether functionality, 49, and the other with a free hydroxyl moiety, 51. The tetrafluorophenyl esters, 50 and 52, can be prepared readily using tetrafluorophenyl trifluoroacetate (TFP-TFA). Choice of these derivatives will be dependent on the specific requirements of subsequent reactions. As in other multibiotin-containing compounds in accordance with the invention, a linker moiety is added prior to the addition to the cross-linker with at least tri-functionality.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 45

38
C₂₃H₂₉F₄N₃O₅S [ No CAS ]
[ 142685-25-4 ]
C₁₉H₂₁F₄N₃O₅S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		This compound can be conjugated with chemical entities bearing amines or a linker, such as 4,7,10-trioxa-1,13-tridecanediamine, and added before the reaction with the cross-linker. The t-Boc protecting group can be removed with TFA. The resulting free amine will have a positive charge at physiologic conditions. The net charge of the multibiotin containing compound according to the invention is dependent on the number of biotin-lysine adducts added in addition to the other charged moieties present. The addition of charged species generally improves the water solubility of multi-biotin-containing compounds; however, alteration of charges on the species may not be desired. Therefore, in certain circumstances, it may be desirable to increase the aqueous solubility of biotin multimers by the addition of another, non-charged species. This can be achieved by preparation of a biotin-serine adduct as shown below. Two (2) biotin-serine adducts can be prepared, one with a t-Bu ether functionality, 49, and the other with a free hydroxyl moiety, 51. The tetrafluorophenyl esters, 50 and 52, can be prepared readily using tetrafluorophenyl trifluoroacetate (TFP-TFA). Choice of these derivatives will be dependent on the specific requirements of subsequent reactions. As in other multibiotin-containing compounds in accordance with the invention, a linker moiety is added prior to the addition to the cross-linker with at least tri-functionality.

Reference： [1]Patent: US2006/228325,2006,A1 .Location in patent: Page/Page column 45

39
[ 586-89-0 ]
[ 142685-25-4 ]
[ 944251-26-7 ]

Yield	Reaction Conditions	Operation in experiment
96.5%	With triethylamine; In N,N-dimethyl-formamide; at 20℃; for 0.08333330000000001h;	Ig (6.1 mmol) 4-Acetylbenzoic acid (29) and 3.45 mL Triethylamine (4eq) were dissolved in 10 mL DMF, followed the addition of 3.2g of 75% pure TFP-TFA. HPLC showed that the reaction was complete after 5 min at rt. The mixture was diluted with 90 mL DI water and stirred for 5 min. The precipitate was collected by filtration and washed with DI water. This yielded 1.836g (96.5%) of 30 as a gray-yellow solid of. MS+Na 335.0298; ELSD = 13.89 min

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 25

40
C₁₀₆H₁₈₀N₁₂O₄₀S₂ [ No CAS ]
[ 142685-25-4 ]
C₁₁₂H₁₈₀F₄N₁₂O₄₀S₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In N,N-dimethyl-formamide; at 20℃; for 0.166667h;	TFAOTFP (10 mg, 38.2 mmol) was added to a solution of compound 10 (50 mg, 21.5 mmol), triethylamine (6 mL, 43mmol) and anhydrous DMF (4 mL) at rt, then the resultant solution was stirred at rt for 10 min. After the solution was washed with 10% EtOAc/hexanes (3 x 15 mL) to provide 11 as a residue.

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 20

41
[ 1415981-79-1 ]
[ 142685-25-4 ]
BOC-dPEG₁₂-CO₂H-TFP [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
86%	With triethylamine; In N,N-dimethyl-formamide; at 0℃; for 0.5h;	TFAOTFP (0.47 g, 1.79 mmol) was added slowly to a solution of BOC-dPEGi2- CO2H (1.0 g, 1.39 mmol), triethylamine (0.39 mL, 2.79 mmol) and anhydrous DMF (10 mL) under ice-bath temperature, then the resultant solution was stirred at the same temperature for 30 min. The solution was evaporated by rotvap evaporator under vacuum, then the residue was washed with 5% EtOAc/hexanes (3 x 20 mL), dried under vacuum for 4 h to afford BOC-dPEG I2-CO2-TFP as a colorless oil product. Yield 1.02 g (86%). HRMS (ES+) calcd for C38H63F4NNaOi6 (M+Na)+: 888.3981. Found: 888.3991. HPLC 13.6 min.

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 21
[2]Nuclear Medicine and Biology,2021,vol. 92,p. 217 - 227

42
BOC-NHNHCO-PhCONH-dPEG₂₄-CO₂H [ No CAS ]
[ 142685-25-4 ]
BOC-NHNHCO-PhCONH-dPEG₂₄-CO₂H-TFP [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
96%	With triethylamine; In acetonitrile; at 0℃; for 0.333333h;	TFAOTFP (73 mg, 0.28 mmol) was added slowly to a solution of BOC-NHNHCO-Ph-CONH-dPEG24-CO2H (300 mg, 0.22 mmol), triethylamine (45 mL, 0.32 mmol) and anhydrous CH3CN (15 mL) under ice-bath temperature, then the resultant solution was stirred at the same temperature for 20 min. The solution was evaporated by rotvap evaporator under vacuum, then th< residue was washed with 10% EtOAc/hexanes (3 x 20 mL), dried under vacuum for 4 h to afford BOC-dPEG24-CO2-TFP as a colorless oil product. Yield 319 mg (96%). HPLC 12.9 min.

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 23

43
C₆₂H₁₂₂N₄O₃₁ [ No CAS ]
[ 142685-25-4 ]
C₆₈H₁₂₂F₄N₄O₃₁ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In acetonitrile; at 0℃; for 0.2h;	To 150 μL of TFP-TFA in 2 mL Acetonitrile at O0C was added 102 mg of 26 (0.072 mmol) and 200 μL triethylamine. The reaction was allowed to proceed for 12 min. The product was precipitated by addition of 10% ether in hexanes and washed with 2 x 10 mL of that solvent. This yielded 15 mg of 27.

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 24

44
C₃₆H₆₁NO₁₆ [ No CAS ]
[ 142685-25-4 ]
C₄₂H₆₁F₄NO₁₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In acetonitrile; at 0℃; for 0.116667h;	To a solution of 228 mg 32 (0.298 mmol) and 168 μL (4eq) Triethylamine in 2 mL acetonitrile was added TFP-TFA at 00C. HPLC showed that the reaction was complete after 7 minutes. The mixture was concentrated and dried in vacuo before dissolving in 0.5 mL EtOAc and transferring to a flask containing 10 mL of 1 :9 ether:Hexanes. The top <n="27"/>layer was removed and the bottom layer was treated with another 10 mL of ether.Hexanes. The bottom layer was concentrated to a viscous brown oil of 33. ELSD = 12.63 min

Reference： [1]Patent: WO2007/80114,2007,A2 .Location in patent: Page/Page column 25-26

45
C₁₉H₃₃N₃O₇S [ No CAS ]
[ 142685-25-4 ]
C₂₅H₃₃F₄N₃O₇S [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2008,vol. 130,p. 16466 - 16467

46
[ 318511-05-6 ]
[ 142685-25-4 ]
[ 905575-65-7 ]

Reference： [1]Organic and Biomolecular Chemistry,2010,vol. 8,p. 4059 - 4062

47
[ 295322-44-0 ]
[ 142685-25-4 ]
[ 295322-45-1 ]

Reference： [1]Bioconjugate Chemistry,2010,vol. 21,p. 1225 - 1238

48
[ 79360-05-7 ]
[ 142685-25-4 ]
[ 158041-85-1 ]

Reference： [1]Bioconjugate Chemistry,2010,vol. 21,p. 1225 - 1238

49
5-((4S)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid [ No CAS ]
[ 142685-25-4 ]
biotin-2,3,5,6-tetrafluorophenyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
95%	With triethylamine; In N,N-dimethyl-formamide; for 0.5h;	EXAMPLE 1 - Use of tetrazine microbubbles to target VEGFR2-expressing cells [0032] Tetrazine-functionalized bubbles were prepared using commercially available streptavidin coated MB’s (MicroMarker Target-Ready contrast agents, VisualSonics) and a biotinylated tetrazine. The biotin-tetrazine derivative was synthesized from biotin in four high yielding steps as shown in Figure 1 using the reagents and conditions as follows for each step: a) <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>, DMF, TEA, 30 mm, 95%; b) 6-amino-hexanoic acid, DMF, TEA, 75 C, 12 h, 91%; c) <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>, DMF, DMSO, 80 C, 1 h, 96%; d) 4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, DMF, TEA, 1 h, 75%. DMF = dimethylformamide, TEA = triethylamine, DMSO = dimethylsulfoxide. The desired product was ultimately obtained by coupling commercially available 4-( 1,2,4,5 -tetrazin-3 - yl)phenyl)methanamine hydrochloride (6.2mg, 0.03 3 mmol; Sigma-Aldrich) with 6- biotinamidohexanoic TFP ester (25 mg, 0.049 mrnol) at room temperature. After semi- preparative HPLC, the biotin-tetrazine derivative was isolated in a 75% yield. The product was stable in the freezer for more than 6 months. The TCO-conjugated antibody (TCO-antiVEGFR2) was prepared by combining an excess (20 equiv.) of commercially available (E)-cyclooct-4-enyl- 2,5-dioxopyrrolidin-1-yl carbonate (TCO-NHS) with antiVEGFR2 (eBioscience) at 4 C overnight at pH 9-9.5. After purification using a 30 kDa centrifugal filter (Amicon Ultra-0.5) MALDI-TOF MS showed the product had an average of 3 TCO derivatives per antibody.

Reference： [1]Angewandte Chemie - International Edition,2014,vol. 53,p. 6459 - 6463
Angew. Chem.,2014,vol. 53,p. 6459 - 6463,5
[2]Patent: WO2015/117235,2015,A1 .Location in patent: Paragraph 0032

50
[ 1428124-80-4 ]
[ 142685-25-4 ]
6-biotinamidohexanoic TFP ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
96%	In dimethyl sulfoxide; N,N-dimethyl-formamide; at 80℃; for 1.0h;	EXAMPLE 1 - Use of tetrazine microbubbles to target VEGFR2-expressing cells [0032] Tetrazine-functionalized bubbles were prepared using commercially available streptavidin coated MB’s (MicroMarker Target-Ready contrast agents, VisualSonics) and a biotinylated tetrazine. The biotin-tetrazine derivative was synthesized from biotin in four high yielding steps as shown in Figure 1 using the reagents and conditions as follows for each step: a) <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>, DMF, TEA, 30 mm, 95%; b) 6-amino-hexanoic acid, DMF, TEA, 75 C, 12 h, 91%; c) <strong>[142685-25-4]2,3,5,6-tetrafluorophenyl trifluoroacetate</strong>, DMF, DMSO, 80 C, 1 h, 96%; d) 4-(1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, DMF, TEA, 1 h, 75%. DMF = dimethylformamide, TEA = triethylamine, DMSO = dimethylsulfoxide. The desired product was ultimately obtained by coupling commercially available 4-( 1,2,4,5 -tetrazin-3 - yl)phenyl)methanamine hydrochloride (6.2mg, 0.03 3 mmol; Sigma-Aldrich) with 6- biotinamidohexanoic TFP ester (25 mg, 0.049 mrnol) at room temperature. After semi- preparative HPLC, the biotin-tetrazine derivative was isolated in a 75% yield. The product was stable in the freezer for more than 6 months. The TCO-conjugated antibody (TCO-antiVEGFR2) was prepared by combining an excess (20 equiv.) of commercially available (E)-cyclooct-4-enyl- 2,5-dioxopyrrolidin-1-yl carbonate (TCO-NHS) with antiVEGFR2 (eBioscience) at 4 C overnight at pH 9-9.5. After purification using a 30 kDa centrifugal filter (Amicon Ultra-0.5) MALDI-TOF MS showed the product had an average of 3 TCO derivatives per antibody.

Reference： [1]Angewandte Chemie - International Edition,2014,vol. 53,p. 6459 - 6463
Angew. Chem.,2014,vol. 53,p. 6459 - 6463,5
[2]Patent: WO2015/117235,2015,A1 .Location in patent: Paragraph 0032

51
N-(6-(dimethylamino)-9-(2-(4-(ethoxycarbonyl)piperidine-1-carbonyl)phenyl)-3H-xanthen-3-ylidene)-N-methylmethanaminium [ No CAS ]
[ 142685-25-4 ]
C₃₆H₃₂F₄N₃O₄⁽¹⁺⁾ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; In N,N-dimethyl-formamide; at 20℃; for 1.0h;	Example 4 Synthesis of Compound 4 (0671) (0672) To a solution of N-(6-(dimethylamino)-9-(2-(4-(ethoxycarbonyl)piperidine-1-carbonyl)phenyl)-3H-xanthen-3-ylidene)-N-methylmethanaminium (intermediate in Example 2) (20 mg, 0.04 mmol) and dry pyridine (40 μL, 0.50 mmol) in DMF (2 mL), was added 2,3,5,6-tetrafluorophenyl 2,2,2-trifluoroacetate (10 mg, 0.04 mmol). After stirring at room temperature for 1 hour, it was diluted with 20 mL of dichloromethane, washed with 0.1 M HCl three times. The solvent was removed under vacuum to give Compound 4. 1H-NMR (DMSO-d6): δ 8.10 (s, 1H), 7.85 (t, 1H), 7.60 (t, 2H), 7.10 (m, 2H), 6.45 (m, 2H), 6.40 (m, 3H), 3.03 (t, 12H), 2.74 (m, 4H), 2.04 (m, 1H), 1.58 (t, 4H).

Reference： [1]Patent: US2017/44372,2017,A1 .Location in patent: Paragraph 0671; 0672

52
[ 756525-91-4 ]
[ 142685-25-4 ]
C₂₂H₃₁F₄NO₈ [ No CAS ]

Reference： [1]Nuclear Medicine and Biology,2021,vol. 92,p. 217 - 227

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 142685-25-4 ]

Fluorinated Building Blocks

[ 1956328-10-1 ]

8-Fluoronaphthalen-2-yl 2,2,2-trifluoroacetate

Similarity: 0.82

Aryls

[ 1956328-10-1 ]

8-Fluoronaphthalen-2-yl 2,2,2-trifluoroacetate

Similarity: 0.82

Esters

[ 1956328-10-1 ]

8-Fluoronaphthalen-2-yl 2,2,2-trifluoroacetate

Similarity: 0.82

Trifluoromethyls

[ 1956328-10-1 ]

8-Fluoronaphthalen-2-yl 2,2,2-trifluoroacetate

Similarity: 0.82

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Ghs Hazard Statements

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere